Impairment of Vα24-Jα18+Vβ11+ natural killer T cells in adult acute lymphoblastic leukemia patients

Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+...

Full description

Saved in:
Bibliographic Details
Published inExperimental cell research Vol. 374; no. 1; pp. 69 - 75
Main Authors Zhao, Haijun, Li, Zhifeng, Xie, Shiting, Luo, Yiming, Zhou, Yong, Deng, Manman, Zeng, Hanyan, Zhao, Jintao, Yu, Lian, Xu, Bing
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients. •Type I NKT cell frequency was significantly reduced in adult B-cell ALL patients.•Type I NKT cells from adult B-cell ALL patients showed lower IL-21 and IL-21R levels.•IL-21R+ NKT cells in ALL showed reduced capacity to promote CD8 T cell responses.•IL-21R+ type I NKT cell-mediated effects required IL-21 release.•IL-21R+ NKT cell was correlated with effector CD8 T cell frequency in ALL patients.
AbstractList Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3 lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21 type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R , but not IL-21R , type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.
Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients. •Type I NKT cell frequency was significantly reduced in adult B-cell ALL patients.•Type I NKT cells from adult B-cell ALL patients showed lower IL-21 and IL-21R levels.•IL-21R+ NKT cells in ALL showed reduced capacity to promote CD8 T cell responses.•IL-21R+ type I NKT cell-mediated effects required IL-21 release.•IL-21R+ NKT cell was correlated with effector CD8 T cell frequency in ALL patients.
Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in patients with adult B-cell acute lymphoblastic leukemia (ALL). We first identified type I NKT cells as Vα24-Jα18 and Vβ11 double-positive CD3+ lymphocytes. Using this method, we found that the adult B-cell ALL patients presented significantly lower level of type I NKT cells than the age- and sex-matching control subjects. The expression of IL-21 by type I NKT cells was then examined using intracellular flow cytometry, which showed that with α-GalCer stimulation, the adult B-cell ALL patients presented significantly lower level of IL-21+ type I NKT cells than control subjects. By both flow cytometry and ELISA, we found that the vast majority of IL-21-expressing type I NKT cells expressed IL-21R, which was also reduced in adult B-cell ALL patients. Using an in vitro co-culture system, we demonstrated that IL-21R+, but not IL-21R-, type I NKT cells could promote the IFN-γ, granzyme B, and perforin expression by CD8 T cells in an IL-21-dependent fashion. This type I NKT cell-mediated stimulatory effect was reduced in adult B-cell ALL patients than in control subjects. In addition, we observed a positive correlation between the frequency of IL-21R+ type I NKT cells and the frequencies of IFN-γ-, granzyme B-, and perforin-expressing circulating CD8 T cells in adult B-cell ALL patients directly ex vivo. Overall, this study identified an IL-21-related impairment in type I NKT cells from adult B-cell ALL patients.
Author Xie, Shiting
Zeng, Hanyan
Deng, Manman
Yu, Lian
Luo, Yiming
Xu, Bing
Zhao, Jintao
Zhou, Yong
Zhao, Haijun
Li, Zhifeng
Author_xml – sequence: 1
  givenname: Haijun
  surname: Zhao
  fullname: Zhao, Haijun
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 2
  givenname: Zhifeng
  surname: Li
  fullname: Li, Zhifeng
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 3
  givenname: Shiting
  surname: Xie
  fullname: Xie, Shiting
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 4
  givenname: Yiming
  surname: Luo
  fullname: Luo, Yiming
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 5
  givenname: Yong
  surname: Zhou
  fullname: Zhou, Yong
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 6
  givenname: Manman
  surname: Deng
  fullname: Deng, Manman
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 7
  givenname: Hanyan
  surname: Zeng
  fullname: Zeng, Hanyan
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 8
  givenname: Jintao
  surname: Zhao
  fullname: Zhao, Jintao
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
– sequence: 9
  givenname: Lian
  surname: Yu
  fullname: Yu, Lian
  email: yulian_an_ly@126.com
  organization: Department of Hematology and Rheumatology, Longyan First Hospital, Affiliated to Fujian Medical University, Longyan 364000, PR, China
– sequence: 10
  givenname: Bing
  surname: Xu
  fullname: Xu, Bing
  email: bingxudr@sina.com
  organization: Department of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Medical College of Xiamen University, Xiamen 361003, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30439366$$D View this record in MEDLINE/PubMed
BookMark eNp9kb1uFDEUhS0URDaBJ0BCLpGiGXxt7-xMQYEifoIi0YS0lse-Ft54frA9iH2s8CD7THjZpKFI5eb7jq7POSMn4zQiIa-B1cCgebetd_jbxJozaGuAmrH2GVkB61jFJecnZMUYyEq2fHNKzlLaskK00Lwgp4JJ0YmmWRF3NczaxwHHTCdHb_f3XFZf9_fQXtzu_wBc0FHnJepA73wIGOkNNRhCon6k2i4hU22WjDTshvnH1Aedsjc04HKHg9d01tmX6PSSPHc6JHz18J6T758-3lx-qa6_fb66_HBdGb6RuULJ7do4J6QEZ9fYNdrqDTMbg2vpWita2UvXgDWcOd11lvfY9L3oWcd5a1Gck7fH3DlOPxdMWQ0-HQ7WI05LUhzEGkq6bAr65gFd-gGtmqMfdNypx24K0B0BE6eUIjplfC7_mcYctQ8KmDrsoLbq3w7qsIMCUKXl4or_3Mf4p633RwtLRb88RpVMqc-g9RFNVnbyT_p_AduMpTA
CitedBy_id crossref_primary_10_1016_j_clim_2019_05_011
Cites_doi 10.1182/blood-2008-06-161281
10.1038/ni.1942
10.1038/82771
10.4049/jimmunol.1001018
10.1073/pnas.0801631105
10.1200/JCO.2014.59.1636
10.1172/JCI37869
10.4049/jimmunol.167.6.3114
10.3389/fimmu.2013.00438
10.1371/journal.pone.0020702
10.1038/cti.2013.7
10.1155/2012/720803
10.1016/j.it.2016.06.001
10.1128/JVI.01053-10
10.1038/nri3328
10.4049/jimmunol.178.5.2827
10.1155/2015/652875
10.1038/cti.2016.14
10.1084/jem.20022227
10.1056/NEJMoa1605085
10.3389/fimmu.2017.01178
10.1111/j.1476-5381.2012.02108.x
10.1002/eji.201242531
10.1038/nri3369
10.1016/j.clim.2010.10.005
10.4049/jimmunol.1800429
10.1073/pnas.95.10.5690
10.1002/cncr.20668
ContentType Journal Article
Copyright 2018 Elsevier Inc.
Copyright © 2018 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2018 Elsevier Inc.
– notice: Copyright © 2018 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.yexcr.2018.11.008
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1090-2422
EndPage 75
ExternalDocumentID 30439366
10_1016_j_yexcr_2018_11_008
S0014482718308553
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
-DZ
-~X
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAXUO
ABFNM
ABFRF
ABGSF
ABJNI
ABMAC
ABOCM
ABPPZ
ABUDA
ABYKQ
ACDAQ
ACGFO
ACGFS
ACNCT
ACPRK
ACRLP
ADBBV
ADEZE
ADUVX
AEBSH
AEFWE
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
K-O
KOM
L7B
LG5
LX2
M41
MO0
N9A
O-L
O9-
OAUVE
OVD
OZT
P-8
P-9
P2P
PC.
PQQKQ
Q38
RIG
RNS
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPCBC
SSU
SSZ
T5K
TEORI
TWZ
VQA
WH7
Y6R
YZZ
ZA5
ZCA
ZMT
ZU3
~G-
~KM
.55
.GJ
29G
3O-
53G
9M8
AAQXK
AATTM
AAXKI
AAYWO
AAYXX
ABDPE
ABEFU
ABWVN
ABXDB
ACKIV
ACRPL
ACVFH
ADCNI
ADFGL
ADMUD
ADNMO
ADVLN
ADXHL
AEIPS
AETEA
AEUPX
AFJKZ
AFPUW
AGCQF
AGHFR
AGQPQ
AGRDE
AGRNS
AI.
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
ASPBG
AVWKF
AZFZN
BNPGV
CAG
CITATION
COF
FA8
FEDTE
FGOYB
G-2
HLW
HVGLF
HZ~
LPU
MVM
NEJ
OHT
R2-
SBG
SEW
SSH
VH1
WUQ
X7L
X7M
XOL
XPP
YYP
ZGI
ZKB
CGR
CUY
CVF
ECM
EIF
NPM
7X8
EFKBS
ID FETCH-LOGICAL-c274t-e42d5cff3441fd5e96ada70c7ce54f8d384b4f61dc20fa99d2be6bb3b09228de3
IEDL.DBID .~1
ISSN 0014-4827
1090-2422
IngestDate Thu Aug 07 15:06:32 EDT 2025
Wed Feb 19 02:30:11 EST 2025
Thu Apr 24 23:08:31 EDT 2025
Tue Jul 01 00:59:37 EDT 2025
Fri Feb 23 02:12:53 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Acute lymphoblastic leukemia
Natural killer T cells
IL-21
Language English
License Copyright © 2018 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c274t-e42d5cff3441fd5e96ada70c7ce54f8d384b4f61dc20fa99d2be6bb3b09228de3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 30439366
PQID 2135134446
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_2135134446
pubmed_primary_30439366
crossref_citationtrail_10_1016_j_yexcr_2018_11_008
crossref_primary_10_1016_j_yexcr_2018_11_008
elsevier_sciencedirect_doi_10_1016_j_yexcr_2018_11_008
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-01-01
2019-01-00
20190101
PublicationDateYYYYMMDD 2019-01-01
PublicationDate_xml – month: 01
  year: 2019
  text: 2019-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Experimental cell research
PublicationTitleAlternate Exp Cell Res
PublicationYear 2019
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Terabe, Matsui, Park, Mamura, Noben-Trauth, Donaldson (bib11) 2003
Jabbour, Pui, Kantarjian (bib1) 2018
Terabe, Matsui, Noben-Trauth, Chen, Watson, Donaldson (bib10) 2000
Nair, Dhodapkar (bib7) 2017
Coquet, Chakravarti, Kyparissoudis, McNab, Pitt, McKenzie (bib12) 2008
Kawano, Cui, Koezuka, Toura, Kaneko, Sato (bib21) 1998
Coquet, Kyparissoudis, Pellicci, Besra, Berzins, Smyth (bib23) 2007
Nakagawa, Serizawa, Motoki, Sato, Ueno, Iijima (bib19) 2000
Fallarini, Paoletti, Orsi Battaglini, Lombardi (bib29) 2012
Wingender, Krebs, Beutler, Kronenberg (bib24) 2010
Song, Asgharzadeh, Salo, Engell, Wu, Sposto (bib31) 2009
Rossjohn, Pellicci, Patel, Gapin, Godfrey (bib6) 2012
Pilones, Aryankalayil, Demaria (bib8) 2012
Gowda, Roda, Hussain, Ramanunni, Joshi, Schmidt (bib18) 2008; 111
Miura, Kawana, Schust, Fujii, Yokoyama, Iwasawa (bib30) 2010
Kantarjian, Thomas, O’Brien, Cortes, Giles, Jeha (bib3) 2004
Carreño, Saavedra-Ávila, Porcelli (bib33) 2016
Spanoudakis, Hu, Naresh, Terpos, Melo, Reid (bib27) 2009
Coquet, Skak, Davis, Smyth, Godfrey (bib15) 2013; 2
Bai, Picard, Anderson, Chaudhary, Luoma, Jabri (bib13) 2012
Hix, Shi, Brutkiewicz, Stein, Wang, Zhang (bib28) 2011
Bhatt, Matthews, Parvin, Sarosiek, Zhao, Jiang (bib17) 2015; 126
De Santo, Arscott, Booth, Karydis, Jones, Asher (bib32) 2010
Kawano, Nakayama, Kamada, Kaneko, Harada, Ogura (bib22) 1999
Dudek, Martin, Garg, Agostinis (bib20) 2013
Brennan, Brigl, Brenner (bib5) 2013
Altman, Benavides, Das, Bassiri (bib9) 2015
Ngai, Tian, Courtney, Ravari, Guo, Liu (bib16) 2018
Pui, Yang, Hunger, Pieters, Schrappe, Biondi (bib2) 2015
Metelitsa (bib26) 2011
Tian, Zajac, Cell (bib14) 2016
Metelitsa, Naidenko, Kant, Wu, Loza, Perussia (bib25) 2001
Maury, Chevret, Thomas, Heim, Leguay, Huguet (bib4) 2016
Coquet (10.1016/j.yexcr.2018.11.008_bib15) 2013; 2
Kawano (10.1016/j.yexcr.2018.11.008_bib21) 1998
Kantarjian (10.1016/j.yexcr.2018.11.008_bib3) 2004
Wingender (10.1016/j.yexcr.2018.11.008_bib24) 2010
Gowda (10.1016/j.yexcr.2018.11.008_bib18) 2008; 111
Metelitsa (10.1016/j.yexcr.2018.11.008_bib25) 2001
Carreño (10.1016/j.yexcr.2018.11.008_bib33) 2016
Pilones (10.1016/j.yexcr.2018.11.008_bib8) 2012
Altman (10.1016/j.yexcr.2018.11.008_bib9) 2015
Dudek (10.1016/j.yexcr.2018.11.008_bib20) 2013
Coquet (10.1016/j.yexcr.2018.11.008_bib23) 2007
Metelitsa (10.1016/j.yexcr.2018.11.008_bib26) 2011
Bhatt (10.1016/j.yexcr.2018.11.008_bib17) 2015; 126
Nair (10.1016/j.yexcr.2018.11.008_bib7) 2017
Rossjohn (10.1016/j.yexcr.2018.11.008_bib6) 2012
Terabe (10.1016/j.yexcr.2018.11.008_bib11) 2003
Bai (10.1016/j.yexcr.2018.11.008_bib13) 2012
Fallarini (10.1016/j.yexcr.2018.11.008_bib29) 2012
Coquet (10.1016/j.yexcr.2018.11.008_bib12) 2008
Ngai (10.1016/j.yexcr.2018.11.008_bib16) 2018
Miura (10.1016/j.yexcr.2018.11.008_bib30) 2010
Brennan (10.1016/j.yexcr.2018.11.008_bib5) 2013
Terabe (10.1016/j.yexcr.2018.11.008_bib10) 2000
Kawano (10.1016/j.yexcr.2018.11.008_bib22) 1999
Maury (10.1016/j.yexcr.2018.11.008_bib4) 2016
De Santo (10.1016/j.yexcr.2018.11.008_bib32) 2010
Tian (10.1016/j.yexcr.2018.11.008_bib14) 2016
Nakagawa (10.1016/j.yexcr.2018.11.008_bib19) 2000
Spanoudakis (10.1016/j.yexcr.2018.11.008_bib27) 2009
Pui (10.1016/j.yexcr.2018.11.008_bib2) 2015
Hix (10.1016/j.yexcr.2018.11.008_bib28) 2011
Jabbour (10.1016/j.yexcr.2018.11.008_bib1) 2018
Song (10.1016/j.yexcr.2018.11.008_bib31) 2009
References_xml – year: 1999
  ident: bib22
  article-title: Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
  publication-title: Cancer Res.
– year: 2004
  ident: bib3
  article-title: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
  publication-title: Cancer
– year: 2012
  ident: bib8
  article-title: Invariant NKT cells as novel targets for immunotherapy in solid tumors
  publication-title: Clin. Dev. Immunol.
– year: 2009
  ident: bib31
  article-title: Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
  publication-title: J. Clin. Investig.
– year: 2001
  ident: bib25
  article-title: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells
  publication-title: J. Immunol.
– year: 2003
  ident: bib11
  article-title: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte–mediated tumor immunosurveillance
  publication-title: J. Exp. Med.
– volume: 126
  start-page: 1555
  year: 2015
  end-page: 1564
  ident: bib17
  article-title: Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma
  publication-title: Blood. Am. Soc. Hematol.
– year: 2009
  ident: bib27
  article-title: Regulation of multiple myeloma survival and progression by CD1d
  publication-title: Blood
– year: 2015
  ident: bib2
  article-title: Childhood Acute lymphoblastic leukemia: progress through collaboration
  publication-title: J. Clin. Oncol.
– year: 2013
  ident: bib5
  article-title: Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
  publication-title: Nat. Rev. Immunol.
– year: 2010
  ident: bib24
  article-title: Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency
  publication-title: J. Immunol.
– year: 2015
  ident: bib9
  article-title: Antitumor responses of invariant natural killer T cells
  publication-title: J. Immunol. Res.
– year: 1998
  ident: bib21
  article-title: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V 14 NKT cells
  publication-title: Proc. Natl. Acad. Sci.
– start-page: 1
  year: 2018
  end-page: 8
  ident: bib1
  article-title: Progress and Innovations in the management of adult acute lymphoblastic leukemia
  publication-title: JAMA Oncol.
– year: 2000
  ident: bib19
  article-title: Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells
  publication-title: Oncol. Res.
– year: 2012
  ident: bib29
  article-title: Invariant NKT cells increase drug-induced osteosarcoma cell death
  publication-title: Br. J. Pharmacol.
– year: 2018
  ident: bib16
  article-title: IL-21 selectively protects CD62L + NKT cells and enhances their effector functions for adoptive immunotherapy
  publication-title: J. Immunol.
– year: 2013
  ident: bib20
  article-title: Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity
  publication-title: Front. Immunol.
– year: 2007
  ident: bib23
  article-title: IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production
  publication-title: J. Immunol.
– year: 2008
  ident: bib12
  article-title: Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population
  publication-title: Proc. Natl. Acad. Sci.
– year: 2010
  ident: bib30
  article-title: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV
  publication-title: J. Virol.
– year: 2016
  ident: bib4
  article-title: Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
  publication-title: N. Engl. J. Med.
– year: 2010
  ident: bib32
  article-title: Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A
  publication-title: Nat. Immunol.
– year: 2012
  ident: bib13
  article-title: The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR
  publication-title: Eur. J. Immunol.
– year: 2000
  ident: bib10
  article-title: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
  publication-title: Nat. Immunol.
– year: 2012
  ident: bib6
  article-title: Recognition of CD1d-restricted antigens by natural killer T cells
  publication-title: Nat. Rev. Immunol.
– volume: 111
  start-page: 4723
  year: 2008
  end-page: 4730
  ident: bib18
  article-title: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. blood
  publication-title: Am. Soc. Hematol.
– volume: 2
  start-page: e6
  year: 2013
  ident: bib15
  article-title: IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma
  publication-title: Clin. Transl. Immunol. Nat. Publ. Group
– year: 2017
  ident: bib7
  article-title: Natural killer T cells in cancer immunotherapy
  publication-title: Front. Immunol.
– year: 2011
  ident: bib26
  article-title: Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
  publication-title: Clin. Immunol.
– year: 2011
  ident: bib28
  article-title: CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis
  publication-title: PLoS One
– year: 2016
  ident: bib33
  article-title: Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
  publication-title: Clin. Transl. Immunol.
– year: 2016
  ident: bib14
  article-title: Differentiation: consider the context
  publication-title: Trends Immunol.
– year: 2009
  ident: 10.1016/j.yexcr.2018.11.008_bib27
  article-title: Regulation of multiple myeloma survival and progression by CD1d
  publication-title: Blood
  doi: 10.1182/blood-2008-06-161281
– year: 2010
  ident: 10.1016/j.yexcr.2018.11.008_bib32
  article-title: Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1942
– year: 2000
  ident: 10.1016/j.yexcr.2018.11.008_bib10
  article-title: NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway
  publication-title: Nat. Immunol.
  doi: 10.1038/82771
– year: 2010
  ident: 10.1016/j.yexcr.2018.11.008_bib24
  article-title: Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1001018
– year: 2008
  ident: 10.1016/j.yexcr.2018.11.008_bib12
  article-title: Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.0801631105
– year: 2015
  ident: 10.1016/j.yexcr.2018.11.008_bib2
  article-title: Childhood Acute lymphoblastic leukemia: progress through collaboration
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.59.1636
– year: 2009
  ident: 10.1016/j.yexcr.2018.11.008_bib31
  article-title: Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI37869
– year: 1999
  ident: 10.1016/j.yexcr.2018.11.008_bib22
  article-title: Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
  publication-title: Cancer Res.
– year: 2001
  ident: 10.1016/j.yexcr.2018.11.008_bib25
  article-title: Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.167.6.3114
– volume: 111
  start-page: 4723
  year: 2008
  ident: 10.1016/j.yexcr.2018.11.008_bib18
  article-title: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. blood
  publication-title: Am. Soc. Hematol.
– year: 2013
  ident: 10.1016/j.yexcr.2018.11.008_bib20
  article-title: Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2013.00438
– year: 2011
  ident: 10.1016/j.yexcr.2018.11.008_bib28
  article-title: CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0020702
– volume: 2
  start-page: e6
  year: 2013
  ident: 10.1016/j.yexcr.2018.11.008_bib15
  article-title: IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma
  publication-title: Clin. Transl. Immunol. Nat. Publ. Group
  doi: 10.1038/cti.2013.7
– volume: 126
  start-page: 1555
  year: 2015
  ident: 10.1016/j.yexcr.2018.11.008_bib17
  article-title: Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma
  publication-title: Blood. Am. Soc. Hematol.
– year: 2012
  ident: 10.1016/j.yexcr.2018.11.008_bib8
  article-title: Invariant NKT cells as novel targets for immunotherapy in solid tumors
  publication-title: Clin. Dev. Immunol.
  doi: 10.1155/2012/720803
– year: 2016
  ident: 10.1016/j.yexcr.2018.11.008_bib14
  article-title: Differentiation: consider the context
  publication-title: Trends Immunol.
  doi: 10.1016/j.it.2016.06.001
– year: 2010
  ident: 10.1016/j.yexcr.2018.11.008_bib30
  article-title: CD1d, a sentinel molecule bridging innate and adaptive immunity, is downregulated by the human papillomavirus (HPV) E5 protein: a possible mechanism for immune evasion by HPV
  publication-title: J. Virol.
  doi: 10.1128/JVI.01053-10
– year: 2012
  ident: 10.1016/j.yexcr.2018.11.008_bib6
  article-title: Recognition of CD1d-restricted antigens by natural killer T cells
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3328
– year: 2007
  ident: 10.1016/j.yexcr.2018.11.008_bib23
  article-title: IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.178.5.2827
– year: 2015
  ident: 10.1016/j.yexcr.2018.11.008_bib9
  article-title: Antitumor responses of invariant natural killer T cells
  publication-title: J. Immunol. Res.
  doi: 10.1155/2015/652875
– year: 2016
  ident: 10.1016/j.yexcr.2018.11.008_bib33
  article-title: Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents
  publication-title: Clin. Transl. Immunol.
  doi: 10.1038/cti.2016.14
– year: 2003
  ident: 10.1016/j.yexcr.2018.11.008_bib11
  article-title: Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte–mediated tumor immunosurveillance
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20022227
– start-page: 1
  year: 2018
  ident: 10.1016/j.yexcr.2018.11.008_bib1
  article-title: Progress and Innovations in the management of adult acute lymphoblastic leukemia
  publication-title: JAMA Oncol.
– year: 2016
  ident: 10.1016/j.yexcr.2018.11.008_bib4
  article-title: Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1605085
– year: 2017
  ident: 10.1016/j.yexcr.2018.11.008_bib7
  article-title: Natural killer T cells in cancer immunotherapy
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01178
– year: 2012
  ident: 10.1016/j.yexcr.2018.11.008_bib29
  article-title: Invariant NKT cells increase drug-induced osteosarcoma cell death
  publication-title: Br. J. Pharmacol.
  doi: 10.1111/j.1476-5381.2012.02108.x
– year: 2012
  ident: 10.1016/j.yexcr.2018.11.008_bib13
  article-title: The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.201242531
– year: 2000
  ident: 10.1016/j.yexcr.2018.11.008_bib19
  article-title: Antitumor activity of alpha-galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells
  publication-title: Oncol. Res.
– year: 2013
  ident: 10.1016/j.yexcr.2018.11.008_bib5
  article-title: Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri3369
– year: 2011
  ident: 10.1016/j.yexcr.2018.11.008_bib26
  article-title: Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans
  publication-title: Clin. Immunol.
  doi: 10.1016/j.clim.2010.10.005
– year: 2018
  ident: 10.1016/j.yexcr.2018.11.008_bib16
  article-title: IL-21 selectively protects CD62L + NKT cells and enhances their effector functions for adoptive immunotherapy
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1800429
– year: 1998
  ident: 10.1016/j.yexcr.2018.11.008_bib21
  article-title: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated V 14 NKT cells
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.95.10.5690
– year: 2004
  ident: 10.1016/j.yexcr.2018.11.008_bib3
  article-title: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
  publication-title: Cancer
  doi: 10.1002/cncr.20668
SSID ssj0008816
Score 2.2752123
Snippet Type I natural killer T (NKT) cells are attractive candidates for cancer immunotherapy. In this study, we examined the characteristics of type I NKT cells in...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 69
SubjectTerms Acute lymphoblastic leukemia
Adult
Aged
B-Lymphocytes - immunology
CD8-Positive T-Lymphocytes - immunology
Female
Humans
IL-21
Interleukins - blood
Lymphocyte Count
Male
Middle Aged
Natural killer T cells
Natural Killer T-Cells - immunology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology
Receptors, Antigen, T-Cell, alpha-beta - metabolism
Receptors, Interleukin-21 - metabolism
Title Impairment of Vα24-Jα18+Vβ11+ natural killer T cells in adult acute lymphoblastic leukemia patients
URI https://dx.doi.org/10.1016/j.yexcr.2018.11.008
https://www.ncbi.nlm.nih.gov/pubmed/30439366
https://www.proquest.com/docview/2135134446
Volume 374
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYQFRKXqqWFbh_IlXqjgfUjjnNEqGihghMgblb8kgJLFrG7EnvhP9Efsr-pM04CqtRy6DGRHUffjMcz1sw3hHwLZRDcQaQatHSZLEOZWetVxiyEzwW3FS-xdvjkVI3O5fFlfrlCDvpaGEyr7Gx_a9OTte7e7HVo7t3WNdb4QjCgORhXgclWyPgpZYFavvvwnOahdWp_ioMzHN0zD6Ucr0W4d0gKyvQuUnlij8m_n07_8j7TKXT4hrzu3Ee63_7hW7ISmg2y1jaUXLwj8Qh2d32HN350EunF8pHL7Hj5yPTOxfIXYzs0EXnCF65TDSA9o3hzP6V1QxMTB63cfBboeAFCnljwrGEdOg7z63BTV7QjYZ2-J-eHP84ORlnXSSFzEHXOsiC5z12MApyf6PNQqspXxdAVLuQyai-0tDIq5h0fxqosPbdBWStAYJxrH8QmWW0mTfhAaMEcGzqQZ144WQisg7Vegx4wWXhZxQHhPYLGdTTj2O1ibPp8siuTYDcIOwQgBmAfkO9Pk25blo2Xh6teNOYPZTFwDrw88WsvSAPbCBGumjCZTw3HToUAj1QDstVK-OlPBJYPC6U-_u-yn8g6PJXtzc1nsjq7m4cv4MvM7HZS1m3yav_o5-j0N4f69dE
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxELZKKgQXxJsABSNxK0vjx3q9x6pqlfSRU1r1Zq1f0rZhUzWJRH5W-SH5TczsIxIS7aHXXb_0jT2esWa-IeR7yIPgDjzVoKVLZB7yxFqvEmbBfc64LXiOucNnYzU8l8eX6eUWOehyYTCsstX9jU6vtXX7Za9Fc--mLDHHF5wBzUG5Cgy2Ek_INrJTpT2yvT86GY43ClnrugIqtk-wQ0c-VId5rcJvh7ygTP9ENk8sM_n_C-o-A7S-iI5ekhetBUn3m0W-Iluhek2eNjUlV29IHMEBL2_x0Y_OIr1Y33GZHK_vmN69WP9hbJfWXJ4wwnWdBkgnFB_v57SsaE3GQQu3XAQ6XYGcZxaMa5iHTsPyOvwqC9rysM7fkvOjw8nBMGmLKSQOHM9FEiT3qYtRgP0TfRpyVfgiG7jMhVRG7YWWVkbFvOODWOS55zYoawXIjHPtg3hHetWsCh8IzZhjAwciTTMnM4GpsNZr2ApMZl4WsU94h6BxLdM4FryYmi6k7MrUsBuEHXwQA7D3yY9Np5uGaOPh5qoTjflnvxi4Ch7u-K0TpIGThAgXVZgt54ZjsUKAR6o-ed9IeLMSgRnEQqmPj532K3k2nJydmtPR-OQTeQ5_8uYh5zPpLW6XYQdMm4X90m7dv-80-II
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impairment+of+V%CE%B124-J%CE%B118+%2B+V%CE%B211+%2B+natural+killer+T+cells+in+adult+acute+lymphoblastic+leukemia+patients&rft.jtitle=Experimental+cell+research&rft.au=Zhao%2C+Haijun&rft.au=Li%2C+Zhifeng&rft.au=Xie%2C+Shiting&rft.au=Luo%2C+Yiming&rft.date=2019-01-01&rft.eissn=1090-2422&rft.volume=374&rft.issue=1&rft.spage=69&rft_id=info:doi/10.1016%2Fj.yexcr.2018.11.008&rft_id=info%3Apmid%2F30439366&rft.externalDocID=30439366
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-4827&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-4827&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-4827&client=summon